Novo Nordisk On The Pluses And Minuses Of The UK Post-Brexit R&D Environment
R&D Good But Batch-Testing Accord And Medicines Uptake Concern
Post-Brexit Britain offers a fertile R&D ecosystem, but it needs to improve uptake in novel medicines there and strike a lasting deal with the EU over batch testing, Novo Nordisk’s UK general manager Pinder Sahota tells Scrip.
